Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

ds that bind selectively to melatonin receptors are candidates to treat sleep disorders, including Circadian Rhythm Sleep Disorders (CRSDs), and additionally are believed to offer potential benefits in mood disorders.  Tasimelteon is currently in Phase III stage of development for the treatment of sleep disorders and CRSDs and is ready for Phase II trials for the treatment of depression.  On January 19, 2010, the U.S. Food and Drug Administration (FDA) granted orphan drug designation status for tasimelteon in a specific CRSD, Non-24-Hour Sleep/Wake Disorder in blind persons.  The FDA grants orphan drug designation to drugs that may provide significant therapeutic advantage over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per year.  Orphan drug designation provides potential financial and regulatory incentives, including study design assistance, tax credits, waiver of FDA user fees, and up to seven years of market exclusivity upon marketing approval.  As Vanda continues to explore the path to a New Drug Application (NDA) for tasimelteon, the orphan drug designation in Non-24 Hour Sleep/Wake Disorder has the potential to strengthen the tasimelteon program by offering clinical development and commercialization benefits.

FINANCIAL DETAILS

  • Operating Expenses.  R&D expenses of $2.3 million for the fourth quarter of 2009 consisted primarily of $0.9 million of salaries and benefits, $0.5 million of non-cash stock based compensation costs for R&D personnel, $0.3 million in consulting fees and $0.2 million for an on-going carcinogenicity study.  This compares to $2.1 million for the third quarter of 2009 and '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... 12 months ended December 31, 2014.  ... or ($0.05) per share, for the three months ended ...
(Date:3/26/2015)... Bruno, CA (PRWEB) March 26, 2015 ... (CRO), announced today several management and executive appointments ... of Chief Financial Officer (CFO) and member of the ... President of Business Operations, and Sue Dowden will assume ... Taricco, co-founder and current Chief Operations Officer (COO), has ...
(Date:3/26/2015)... March 26, 2015  BioNano Genomics, Inc., the leader ... Salyer as chief commercial officer. Salyer has more ... sales teams in life sciences. At BioNano, Salyer will ... a genome-mapping platform to assemble a comprehensive view of ... To date, 32 institutions located in the ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Die Today From a Preventable Lung Disease -- LONDON, October 14, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Oct. 13 Cell Biosciences, Inc. today announced that ... Convergent Bioscience Ltd. for approximately U.S. $12 million in ... end of October, 2010. Convergent Bioscience was ... its headquarters in Toronto, Ontario. Convergent pioneered the use ...
... batteries promises to overcome some of the obstacles long ... with a flat disc design allows the battery to ... to work published by Pacific Northwest National Laboratory in ... a trade journal. Researchers say these sodium-beta batteries ...
Cached Biology Technology:550 People Across Europe Will Die Today From a Preventable Lung Disease 2550 People Across Europe Will Die Today From a Preventable Lung Disease 3550 People Across Europe Will Die Today From a Preventable Lung Disease 4550 People Across Europe Will Die Today From a Preventable Lung Disease 5550 People Across Europe Will Die Today From a Preventable Lung Disease 6550 People Across Europe Will Die Today From a Preventable Lung Disease 7550 People Across Europe Will Die Today From a Preventable Lung Disease 8550 People Across Europe Will Die Today From a Preventable Lung Disease 9Cell Biosciences to Acquire Convergent Bioscience 2Planar power 2
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... In what amounted to a kind of ... data from 175 fields in Illinois, Wisconsin, and Minnesota shed ... the most troublesome weeds, the results also revealed some of ... and sweet corn yield in the Midwest. "Rather than ...
... News headlines are filled with discussion and debate ... Conference in Copenhagen. As expected, the majority ... focused on traditional environmental measures - regulations to ... etc. A new book Paradise Regained: The ...
... such as pomegranates, that contain anti-aromatase phytochemicals reduces the ... a study published in the January issue of ... Association for Cancer Research. Pomegranate is enriched ... as shown in this study, appear to be responsible ...
Cached Biology News:Sweet corn study provides large-scale picture of better fields 2Sweet corn study provides large-scale picture of better fields 3Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Natural compounds in pomegranates may prevent growth of hormone-dependent breast cancer 2
... exceptionally sensitive nucleic acid gel stain has bright ... in gels, making it ideal for detecting dsDNA ... transilluminators. SYBR Green I nucleic acid stain ... real-time PCR assays and bandshift assays. A ...
... 1) Persistent Analysis Environment 2) Dot ... etc. 3) Software Compensation 4) Cell ... Kinetics Platform 7) Intelligent batch generation of ... smoothing 9) Single drag-and-drop operations to perform ...
Synonym: modified Grace's Insect medium...
Eagle's Ham's amino acids; EHAA...
Biology Products: